Category Archives: lorlatinib – Lorbrena by Pfizer

Article on latest develpments

In January 2016 an article was published that reviewed the current status of nine 2nd generation and 3rd generation ALK inhibitors, some HSP 90 inhibitors and briefly 2 immunotherapies for lung cancer. Much of that research has been described in … Continue reading

Posted in alectinib - Alecensa from Chugai - Roche - GenenTech, ASP3026 from Astellas, brigatinib-Alunbrig from Takeda, CEP-37440, ceritinib - Zykadia from Novartis, Imunotherapies, lorlatinib - Lorbrena by Pfizer, Lung cancer, NMS-E628, Potential Treatments, Research, Resistance to treatment, RXDX-101 - entrectinib - by Ignyta, Side Effects, TSR-011 from Tesaro, X-396 - ensartinib from Xcovrery | Leave a comment

Article by Dr. Shaw

Dr. Shaw discusses the recent approval of Alectinib and the treatment implications now that there are 3 ALK inhibitors approved by the FDA. http://www.ascopost.com/issues/january-25-2016/the-evolving-treatment-landscape-of-alk-positive-nsclc/

Posted in alectinib - Alecensa from Chugai - Roche - GenenTech, Brain metastases, ceritinib - Zykadia from Novartis, crizotinib - Xalkori from Pfizer, Imunotherapies, lorlatinib - Lorbrena by Pfizer, Lung cancer, Potential Treatments, Research | Leave a comment

Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.

Patients taking Pfizer’s Lorlatinib (after developing resistance to Crizotinib) can develop the L1198F mutation. The L1198F mutation causes the cancer cells that were previously resistant to Crizotinib to become sensitive to Crizotinib again. Essentially the two drugs can require mutually … Continue reading

Posted in Brain metastases, crizotinib - Xalkori from Pfizer, lorlatinib - Lorbrena by Pfizer, Lung cancer, Potential Treatments, Research, Resistance to treatment | Leave a comment

Survey of ALK inhibitors effects on brain mets

This survey summarizes the results of other research to describe the current level of knowledge about how effective different ALK inhibitors are at treating brain mets. Inhibitors that are discussed include crizotinib, ceritinib, alectinib, AP26113 (brigatinib) and PF-06463922 (lorlatinib). http://www.thecco.net/article/view/6520/7543

Posted in alectinib - Alecensa from Chugai - Roche - GenenTech, Brain metastases, brigatinib-Alunbrig from Takeda, ceritinib - Zykadia from Novartis, crizotinib - Xalkori from Pfizer, lorlatinib - Lorbrena by Pfizer, Lung cancer, Potential Treatments, Research | Leave a comment

06463922 phase 2 trial has started

A phase 2 trial for 06463922 – lorlatinib by Pfizer has started. To find out more details go to clinicaltrials.gov.

Posted in lorlatinib - Lorbrena by Pfizer, Lung cancer, Potential Treatments | Leave a comment

PF-3922 Phase 1 trial

Abstract # 8018 is about a Phase 1 study of PF- 06463922 (3922). 22 patients were studied (18 ALK+ & 4 ROS1+). 17 had central nervous system (CNS) metastases and 19 had prior ALK inhibitor treatment (either 1 or 2). … Continue reading

Posted in Brain metastases, lorlatinib - Lorbrena by Pfizer, Lung cancer, Potential Treatments, Research | Leave a comment

ASCO links

Here are 18 ALK+ related abstract links related to the drugs listed below. On the ASCO website 77 abstracts refered to both “ALK” and “Inhibitor”.  When I get a chance I will write up a summary on some of the … Continue reading

Posted in alectinib - Alecensa from Chugai - Roche - GenenTech, Brain metastases, brigatinib-Alunbrig from Takeda, ceritinib - Zykadia from Novartis, lorlatinib - Lorbrena by Pfizer, Lung cancer, Potential Treatments, Research, RXDX-101 - entrectinib - by Ignyta, Side Effects, TSR-011 from Tesaro | Leave a comment

Pfizer update

Pfizer announced that in 2015 the are going to start trials that combine imunitherapy (PDL-1 and PD-1) drugs with its two ALK inhibitor drugs. Pfizer is planning a potential pivotal study of PF-06463922 starting in 2015. By the end of … Continue reading

Posted in crizotinib - Xalkori from Pfizer, Imunotherapies, lorlatinib - Lorbrena by Pfizer | Leave a comment